Health Bulletin 5/ August/ 2023 - Video

Here are the Top Health stories for the day

'Honey' trap? Dabur clarifies on presence of cancer-causing chemicals in product, says report motivated, baseless

Terming the claim as "motivated" and "baseless", Dabur India Ltd has junked the report about the presence of cancer-causing substance in its honey and clarified that every batch of honey that the company produces, complies with FSSAI standards.

The Dabur Honey and Chyawanprash maker's revenue in April-June rose nearly 11% to 31.30 billion rupees, led largely by growth in its consumer care business. Honey products contribute 6–7% to Dabur's revenues in India.

For more details click on the given link:

'Honey' Trap? Dabur clarifies on presence of cancer causing chemicals in product, says report motivated, baseless

Fake Alert: Viral whatsapp message asking to register on NMC portals sending doctors on a frenzy

A message asking doctors to apply for their Unique Identification Number on the National Medical Commission's (NMC) portal by August 10, 2023, that has gone viral on whatsapp has indeed created a frenzy amongst medical practitioners

Doctors are worried over a recent message, which is being circulated on social media platforms asking doctors to apply for their Unique Identification Number on the National Medical Commission's (NMC) portal by a deadline of August 10, 2023.

For more details click on the given link:

Fake Alert: Viral Whatsapp Message asking to register on NMC portals sending doctors on a frenzy

postpartum depression,USFDA,zuranolone,

For the first time, there’s a pill for postpartum depression

The U.S. Food and Drug Administration has today approved Zurzuvae (zuranolone), the first oral medication indicated to treat postpartum depression (PPD) in adult patients. Zuranolone is a potentially faster-acting, once-daily oral therapy for treatment of postpartum depression with just a 14-day regimen.

PPD is a major depressive episode that typically occurs after childbirth but can also begin during the later stages of pregnancy. Until now, treatment for PPD was only available as an IV injection given by a health care provider in certain health care facilities.

For more details click on the given link:

FDA Approves Zuranolone as first Oral Treatment of Postpartum Depression

Despite new CBME rules, the NEXT Dilemma continues

With the National Medical Commission (NMC) recently releasing its CBME Regulations, governing the entire functioning of MBBS education in India, there were hopes that there would be clarity on the future of the National Exit Test (NExT) in the coming few years.

However, the guidelines have silently ignored to address the question of since when NExT will be applicable adding to the dilemma of thousands of students who are currently pursuing their MBBS.

For more details click on the given link:

Despite new CBME rules, the NEXT Dilemma Continues